In brief
- A US pilot trial combines MDMA with couples therapy to treat PTSD in veterans, involving the civilian partner in the session.
- The eight veterans who completed the program showed a large effect size (d = 1.25) in symptom reduction, which was sustained at follow-up.
- Both partners reported increased mutual support and decreased avoidance; there were no serious adverse effects.
A team from the University of California, San Diego, and the US Department of Veterans Affairs has published the results of a pilot trial that adds MDMA to cognitive-behavioral conjoint therapy for post-traumatic stress disorder. The novelty lies not in the substance—which has been studied for PTSD for years—but in the format: the veteran’s partner joins the therapy session instead of remaining outside.
Therapy for two, not just one
Cognitive-behavioral conjoint therapy was already being used before this trial to treat PTSD by involving the partner, based on the idea that the disorder not only harms the sufferer but also damages the bond with those they live with. What this study adds is the inclusion of two full sessions with MDMA within an eight-session program, with the veteran under the influence of the substance while working with their partner and the therapeutic team. The logic is the same as that supporting the use of MDMA and other entheogens in individual therapy: the substance lowers the fear of reliving trauma and facilitates emotional connection. Here, that is put to work for the relationship, not just the patient.
Trial data
Eight veterans with chronic PTSD and their partners—sixteen people in total—participated within the San Diego VA healthcare system. The design was open-label, without a placebo control group: everyone knew they were receiving MDMA. After the eight therapy sessions and the two days with the substance, PTSD symptoms decreased with a large effect size (d = 1.25), and the improvement was maintained in follow-up evaluations. Both members of each couple reported more mutual support, greater intimacy, and fewer trauma-related avoidance behaviors. The team, led by Leslie A. Morland, reported no serious adverse effects. The study was published on September 4 in the Journal of Traumatic Stress.
Implications
Eight couples is a very small sample size without a placebo group, so we are looking at a preliminary signal, not definitive proof. Larger replications are needed to compare the program with and without MDMA, and to determine if the effect holds up beyond the months of follow-up. The population is also specific: US veterans with combat-related trauma, a profile that does not represent everyone with PTSD. With those caveats, the focus is interesting. PTSD does not live only within the person suffering from it; it leaves a mark on their closest environment, and this trial suggests that psychedelic-assisted therapy can also address that relational aspect. Furthermore, this arrives as the application for approval of MDMA therapy for PTSD continues its review process with the US Food and Drug Administration, and as trials exploring various formats continue to multiply.
Source
- Morland LA, Khalifian CE, Perivoliotis D, et al. Healing together: Results from a pilot trial of 3,4-Methylenedioxymethamphetamine-enhanced cognitive-behavioral conjoint therapy for posttraumatic stress disorder. Journal of Traumatic Stress, September 4, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
